Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) from a strong sell rating to a hold rating in a research report sent to investors on Monday,Zacks.com reports.

LKFT has been the topic of several other reports. Royal Bank Of Canada lifted their price objective on shares of Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. UBS Group reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Finally, Raymond James Financial reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Shares of NASDAQ:LKFT opened at $28.27 on Monday. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -20.05 and a beta of 0.26. Lakefront Biotherapeutics American Depositary Shares has a 1-year low of $26.42 and a 1-year high of $37.78. The company has a 50 day moving average price of $28.27 and a 200 day moving average price of $31.19.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The business had revenue of $1.06 billion for the quarter. On average, sell-side analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Institutional investors have recently modified their holdings of the stock. State of Wyoming acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter valued at $28,000. Van ECK Associates Corp boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% during the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 750 shares during the period. Arax Advisory Partners boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% during the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 1,778 shares during the period. Quadrant Capital Group LLC acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at $134,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at $211,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.